{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:39:21Z","timestamp":1760099961604},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2007,6,20]],"date-time":"2007-06-20T00:00:00Z","timestamp":1182297600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2007,8,22]]},"DOI":"10.1007\/s00277-007-0325-3","type":"journal-article","created":{"date-parts":[[2007,6,19]],"date-time":"2007-06-19T08:10:26Z","timestamp":1182240626000},"page":"741-747","source":"Crossref","is-referenced-by-count":22,"title":["Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia"],"prefix":"10.1007","volume":"86","author":[{"given":"Natasa","family":"Colovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasa","family":"Tosic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanja","family":"Aveic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Djuric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasa","family":"Milic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Bumbasirevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milica","family":"Colovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Pavlovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,6,20]]},"reference":[{"key":"325_CR1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1365-2141.2000.02317.x","volume":"111","author":"FM Abu-Duhier","year":"2000","unstructured":"Abu-Duhier FM, Goodeve AC, Wilson GA et al (2000) FLT3 internal tandem duplications in adult acute myeloid leukemia define a high-risk group. Br J Haematol 111:190\u2013195","journal-title":"Br J Haematol"},{"key":"325_CR2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1046\/j.1365-2141.2001.02850.x","volume":"113","author":"FM Abu-Duhier","year":"2001","unstructured":"Abu-Duhier FM, Goodeve AC, Wilson MA et al (2001) Identification of novel FLT3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 113:983\u2013988","journal-title":"Br J Haematol"},{"key":"325_CR3","first-page":"801","volume":"98","author":"BR Baldwin","year":"2001","unstructured":"Baldwin BR, Tse KF, Small D (2001) Transgenic mice expressing a constitutively activated FLT3 receptor display a myeloproliferative disease phenotype. Blood 98:801","journal-title":"Blood"},{"key":"325_CR4","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","volume":"103","author":"JM Bennet","year":"1985","unstructured":"Bennet JM, Catovsky D, Daniel MT et al (1985) Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French\u2013American\u2013British Cooperative Group. Ann Intern Med 103:620\u2013629","journal-title":"Ann Intern Med"},{"key":"325_CR5","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/sj.leu.2402622","volume":"16","author":"N Boissel","year":"2002","unstructured":"Boissel N, Cayuela JM, Preudhomme C et al (2002) Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 16:1699\u20131704","journal-title":"Leukemia"},{"key":"325_CR6","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/sj.leu.2404246","volume":"20","author":"J Cloos","year":"2006","unstructured":"Cloos J, Goemans BH, Hess CJ et al (2006) Stabillity and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 20:1217\u20131220","journal-title":"Leukemia"},{"key":"325_CR7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ejim.2006.02.028","volume":"17","author":"M Colovic","year":"2006","unstructured":"Colovic M, Jurisic V, Pavlovic S et al (2006) FLT3\/D835 mutation and inversion of chromosome 16 in leukemic transformation of myelofibrosis. Eur J Intern Med 17:434\u2013435","journal-title":"Eur J Intern Med"},{"key":"325_CR8","first-page":"1584","volume":"10","author":"HG Drexler","year":"1996","unstructured":"Drexler HG (1996) Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 10:1584\u20131591","journal-title":"Leukemia"},{"key":"325_CR9","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/blood.V86.5.1661.bloodjournal8651661","volume":"86","author":"M Gabbianelli","year":"1995","unstructured":"Gabbianelli M, Pelosi E, Montesoro E et al (1995) Multilevel effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors\/monocytic precursors. Blood 86:1661\u20131670","journal-title":"Blood"},{"key":"325_CR10","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood 100:1532\u20131542","journal-title":"Blood"},{"key":"325_CR11","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","volume":"92","author":"D Grimwade","year":"1998","unstructured":"Grimwade D, Walker K, Oliver F et al (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1.612 patients entered into MRC AML trial. The Medical Reserch Council Adult and Children\u2019s Leukemia Working Parties. Blood 92:2322\u20132333","journal-title":"Blood"},{"key":"325_CR12","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1182\/blood-2004-11-4430","volume":"150","author":"R Grundler","year":"2005","unstructured":"Grundler R, Miething C, Thiede C et al (2005) FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantational model. Blood 150:4792\u20134800","journal-title":"Blood"},{"key":"325_CR13","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1046\/j.1365-2141.2002.03599.x","volume":"118","author":"T Haferlach","year":"2002","unstructured":"Haferlach T, Schoch C, Schnittger S et al (2002) Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study of 124 patients. Br J Haematol 118:426\u2013431","journal-title":"Br J Haematol"},{"key":"325_CR14","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/sj.onc.1203354","volume":"19","author":"F Hayakawa","year":"2000","unstructured":"Hayakawa F, Towatari M, Kiyoi H et al (2000) Tandem duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19:624\u2013631","journal-title":"Oncogene"},{"key":"325_CR15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0092-8674(95)90404-2","volume":"80","author":"CH Heldin","year":"1995","unstructured":"Heldin CH (1995) Dimerization of cell surface receptors in signal transduction. Cell 80:213\u2013223","journal-title":"Cell"},{"key":"325_CR16","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood-2004-02-0712","volume":"104","author":"J Jiang","year":"2004","unstructured":"Jiang J, Paez JG, Lee JC et al (2004) Identification and characterization of a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood 104:1855\u20131858","journal-title":"Blood"},{"key":"325_CR17","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/sj.leu.2400756","volume":"11","author":"H Kiyoi","year":"1997","unstructured":"Kiyoi H, Naoe T, Yokota S et al (1997) Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocitic leukemia. Leukemia 11:1447\u20131452","journal-title":"Leukemia"},{"key":"325_CR18","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"PD Kottaridis","year":"2001","unstructured":"Kottaridis PD, Gale RE, Frew ME et al (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752\u20131759","journal-title":"Blood"},{"key":"325_CR19","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2002-02-0420","volume":"100","author":"PD Kottaridis","year":"2002","unstructured":"Kottaridis PD, Gale RE, Langabeer SE et al (2002) Studies of FLT3 mutations in paired presentation and relapse samples from patient with acute myloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 100:2393\u20132398","journal-title":"Blood"},{"key":"325_CR20","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/1042819031000067503","volume":"44","author":"PD Kottaridis","year":"2003","unstructured":"Kottaridis PD, Gale RE, Linch DC (2003) Prognostic imlications of the presence of FLT3 mutations in patients with acute myeloid leukemia. Leuk Lymphoma 44:905\u2013913","journal-title":"Leuk Lymphoma"},{"key":"325_CR21","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/0092-8674(91)90010-V","volume":"65","author":"W Matthews","year":"1991","unstructured":"Matthews W, Jordan CT, Wiegand GW et al (1991) A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 65:1143\u20131152","journal-title":"Cell"},{"key":"325_CR22","volume-title":"An international system for human cytogenetic nomenclature","year":"1995","unstructured":"Mitelman F (ed) (1995) An international system for human cytogenetic nomenclature. Karger, Basel, Switzerland"},{"key":"325_CR23","first-page":"1911","volume":"10","author":"M Nakao","year":"1996","unstructured":"Nakao M, Yokota S, Iwai T et al (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10:1911\u20131918","journal-title":"Leukemia"},{"key":"325_CR24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1046\/j.1365-2141.1999.01256.x","volume":"104","author":"Y Nakano","year":"1999","unstructured":"Nakano Y, Kiyoi H, Miyawaki S et al (1999) Molecular evolution of acute myeloid leukemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. Br J Haematol 104:659\u2013664","journal-title":"Br J Haematol"},{"key":"325_CR25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S1470-2045(03)01219-1","volume":"4","author":"PP Piccaluga","year":"2003","unstructured":"Piccaluga PP, Biancchini M, Martinelli G (2003) Novel FLT3 point mutation in acute myeloid leukaemia. Lancet Oncol 4:604","journal-title":"Lancet Oncol"},{"key":"325_CR26","first-page":"111","volume":"90","author":"I Rappold","year":"1997","unstructured":"Rappold I, Ziegler BL, Kohler I et al (1997) Functional and phenotypic characterisation of cord blood and bone marrow subsets expressing FLT3 (CD 135) receptor tyrosine kinase. Blood 90:111\u2013125","journal-title":"Blood"},{"key":"325_CR27","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/sj.leu.2401731","volume":"14","author":"WJ Rombouts","year":"2000","unstructured":"Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE (2000) Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 14:675\u2013683","journal-title":"Leukemia"},{"key":"325_CR28","first-page":"1641","volume":"6","author":"O Rosnet","year":"1991","unstructured":"Rosnet O, Marchetto S, de Lapeyriere O, Birnbaum D (1991) Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR\/CSF1R family. Oncogene 6:1641\u20131650","journal-title":"Oncogene"},{"key":"325_CR29","first-page":"238","volume":"10","author":"O Rosnet","year":"1996","unstructured":"Rosnet O, Buhring HJ, Marchetto S et al (1996) Human FLT3\/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 10:238\u2013248","journal-title":"Leukemia"},{"key":"325_CR30","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1200\/jco.2005.23.16_suppl.6515","volume":"23","author":"MA Sanz","year":"2005","unstructured":"Sanz MA, Martin G, Vellenga E et al (2005) Risk-adapted treatment of acute promyelocytic leukemia: updated results of the Spanish PETHEMA LPA99 Trial using ATRA and anthracycline monochemotherapy. J Clin Oncol 23:6515","journal-title":"J Clin Oncol"},{"key":"325_CR31","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1038\/sj.leu.2404374","volume":"20","author":"MM Schittenhelm","year":"2006","unstructured":"Schittenhelm MM, Yee KWH, Tyner JW et al (2006) FLT3 K663Q is a novel AML-associated oncogenic kinase: determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia 20:2008\u20132014","journal-title":"Leukemia"},{"key":"325_CR32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V100.1.59","volume":"100","author":"S Schnittger","year":"2002","unstructured":"Schnittger S, Schoch C, Dugas M et al (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia (AML): correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study, and usefulness as a marker for detection of minimal residual disease. Blood 100:59\u201366","journal-title":"Blood"},{"key":"325_CR33","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.leukres.2004.12.001","volume":"29","author":"S Scholl","year":"2005","unstructured":"Scholl S, Loncarevic IF, Krause C et al (2005) Analyses of minimal residual disease based on Flt3 mutations in allogeneic peripheral blood stem cell transplantation. Leuk Res 29:849\u2013853","journal-title":"Leuk Res"},{"key":"325_CR34","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-0835-03","volume":"10","author":"LY Shih","year":"2004","unstructured":"Shih LY, Huang CF, Wu JH et al (2004) Heterogenous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples. Clin Cancer Res 10:1326\u20131332","journal-title":"Clin Cancer Res"},{"key":"325_CR35","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/asheducation-2006.1.178","volume":"2006","author":"D Small","year":"2006","unstructured":"Small D (2006) FLT3 mutations: biology and treatment. Hematology 2006:178\u2013184","journal-title":"Hematology"},{"key":"325_CR36","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1182\/blood-2002-03-0953","volume":"100","author":"K Spiekermann","year":"2002","unstructured":"Spiekermann K, Bagrintseva K, Schoch C et al (2002) A new and recurrent activating lenght mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood 100:3423\u20133425","journal-title":"Blood"},{"key":"325_CR37","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2141.2004.04808.x","volume":"124","author":"DL Stirewalt","year":"2004","unstructured":"Stirewalt DL, Mechinchi S, Kussick SJ et al (2004) Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia. Br J Haematol 124:481\u2013484","journal-title":"Br J Haematol"},{"key":"325_CR38","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","volume":"99","author":"C Thiede","year":"2002","unstructured":"Thiede C, Steudel C, Mohr B et al (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326\u20134335","journal-title":"Blood"},{"key":"325_CR39","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0092-8674(90)90801-K","volume":"61","author":"A Ulrich","year":"1990","unstructured":"Ulrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203\u2013212","journal-title":"Cell"},{"key":"325_CR40","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2141.1999.01684.x","volume":"107","author":"K Wheatley","year":"1999","unstructured":"Wheatley K, Burnett AK, Goldstone AH et al (1999) A simple robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukemia derived from MRC AML 10 trial. United Kingdom Medical Resourch Council\u2019s Working Parties. Br J Haematol 107:69\u201379","journal-title":"Br J Haematol"},{"key":"325_CR41","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/sj.leu.2403838","volume":"19","author":"M Yanada","year":"2005","unstructured":"Yanada M, Matsuo K, Suzuki T et al (2005) Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 19:1345\u20131349","journal-title":"Leukemia"},{"key":"325_CR42","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","volume":"97","author":"Y Yamamoto","year":"2001","unstructured":"Yamamoto Y, Kiyoi H, Nakano Y et al (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematological malignancies. Blood 97:2434\u20132439","journal-title":"Blood"},{"key":"325_CR43","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1182\/blood-2002-12-3627","volume":"102","author":"CM Zwaan","year":"2003","unstructured":"Zwaan CM, Meshinchi S, Radich JP et al (2003) FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to celllular drug resistance. Blood 102:2387\u20132394","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-007-0325-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-007-0325-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-007-0325-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T04:52:17Z","timestamp":1587617537000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-007-0325-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,20]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,8,22]]}},"alternative-id":["325"],"URL":"https:\/\/doi.org\/10.1007\/s00277-007-0325-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,20]]}}}